Curaleaf (OTCMKTS:CURLF) Shares Gap Up – Time to Buy?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) shares gapped up before the market opened on Friday . The stock had previously closed at $2.15, but opened at $2.28. Curaleaf shares last traded at $2.13, with a volume of 86,856 shares traded.

Wall Street Analysts Forecast Growth

CURLF has been the subject of several analyst reports. ATB Cormark Capital Markets upgraded Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. Finally, Zacks Research upgraded shares of Curaleaf from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.

Curaleaf Trading Down 7.9%

The company has a quick ratio of 0.76, a current ratio of 1.52 and a debt-to-equity ratio of 1.14. The stock has a market capitalization of $1.35 billion, a P/E ratio of -6.60 and a beta of 0.71. The company has a fifty day simple moving average of $2.35 and a two-hundred day simple moving average of $2.60.

Curaleaf (OTCMKTS:CURLF) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $333.07 million during the quarter, compared to the consensus estimate of $328.70 million. Curaleaf had a negative return on equity of 23.17% and a negative net margin of 18.08%. On average, sell-side analysts expect that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.